PARADIGM-HF Responder Index (AWARD-Class) Calculator
Patient characteristics
Choose the response that best matches the patient's baseline status.
About the AWARD-Class score
AWARD-Class is a clinical score proposed to identify ambulatory patients with heart failure who may demonstrate a super-response after starting sacubitril/valsartan. The derivation study was a retrospective analysis of 185 patients from two tertiary hospitals.
In the original study, super-response at 12 months required no heart-failure admission, death, or heart transplantation, together with a reduction in NT-proBNP of at least 50% and/or an increase in LVEF of at least 10 percentage points.
Score categories
| Total score | Group | Observed event rate |
|---|---|---|
| 0–20 | Low probability | Approximately 24% |
| 21–30 | Intermediate probability | Approximately 47% |
| 31–41 | High probability | Approximately 83% |
Clinical use and limitations
- This score predicts a study-defined response; it does not establish whether sacubitril/valsartan is indicated or safe for an individual patient.
- The model's reported discrimination was modest (AUC 0.720 in the derivation cohort; 0.738 after internal bootstrap validation).
- External validation and local calibration should be considered before applying these event rates to a different population.
- Use current heart-failure guidelines, contraindications, blood pressure, renal function, potassium, tolerability, and clinical judgment when making treatment decisions.
References
The first reference supports the AWARD-Class variables, weights, categories, and observed event rates. PARADIGM-HF is cited separately as the landmark randomized trial of sacubitril/valsartan versus enalapril, not as the derivation study for this score.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.